London, UK (PRWEB) September 28, 2015 -- To date, a host of biotech companies are investigating the cancer vaccine field, which has led to the development of manifold cancer vaccines for various types of cancer. Pharmacos are using these vaccines for clinical studies; some of these vaccines are already available to the patients worldwide. The US and EU markets were the first to approve the cancer vaccines for therapeutic use. In comparison with the RoW, commercialization and development in these regions have already seen remarkable progress.
The attractiveness for cancer vaccines has surged in the last several years owing to their characteristic features like fewer side effects, hypotoxicity and high specificity. Moreover, innovations pertaining to new delivery methods have made them a lucrative option, too. Unlike conventional methods, they can be utilised for targeting the subgroup of cancers without impacting normal cells. Another factor in their favour is their high levels of efficacy versus the currently available cancer therapeutics.
The size of the cancer vaccines market is much smaller if compared to other cancer therapeutics categories. To tap this cancer market category, a lot of global companies are actively pouring money into the development of cancer vaccines.
New in-demand report “Global Cancer Vaccine Market & Clinical Trial Insight” developed by Kuick Research is now available at MarketPublishers.com.
Title: Global Cancer Vaccine Market & Clinical Trial Insight
Published: September, 2015
Price: US$ 4,000.00
The report provides a complete analysis and forecast of the world cancer vaccine marketplace. It provides a deep look at cancer vaccines and describes the mechanisms of action for these vaccines. An overview of adjuvants therapy for cancer vaccines is included. The study provides an analysis of the current market scenario and global cancer vaccine pipeline by indication. It discusses the emergence of personalised cancer vaccines, sheds light on public HPV cancer vaccination programme. The report examines the overall cancer vaccines market dynamics, covering favourable market parameters and commercialisation challenges. The study provides an up-close look at the cancer vaccine development pipeline by stage, indication, company and country. It reviews the 298 cancer vaccine candidates in clinical development; sheds light on the 15 marketed cancer vaccines, by company and indication; and also offers insights into discontinued & suspended cancer vaccine clinical pipeline. The competitive landscape is examines including a discussion of the top 23 market players alongside an overview of their and businesses and product portfolios. The regulatory framework for cancer vaccines development and marketing is reviewed in the study, too.
• overview of the global cancer market;
• discussion of the emergence of personalised cancer vaccines;
• delivery platforms for cancer vaccines;
• mechanism of cancer vaccines;
• worldwide cancer vaccines clinical pipeline by stage, indication, company and country;
• review of the 298 cancer vaccines in clinical development worldwide;
• insights into the 15 of marketed cancer vaccines;
• regulatory framework for cancer vaccines development and marketing;
• and more.
More studies by the publisher can be found at Kuick Research page.
Natalie Aster, The Market Publishers, Ltd, http://marketpublishers.com, +44 2081446009, [email protected]